Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

14°

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

149.58 -1.82 (-1.20%)

Streaming Delayed Price Updated: 3:20 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

51 52 Next >

GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why. ↗

March 13, 2025

A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors.

Via Chartmill

Gilead Presents New HIV Treatment And Cure Research Data ↗

March 12, 2025

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.

Via Benzinga

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

March 11, 2025

Via MarketBeat

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 11, 2025

Via Benzinga

The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts ↗

March 11, 2025

Via Benzinga

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

March 10, 2025

Via Benzinga

P/E Ratio Insights for Gilead Sciences ↗

March 07, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

March 06, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI) ↗

March 11, 2025

Via The Motley Fool

Topics Artificial Intelligence

1 Value Stock with Exciting Potential and 2 to Ignore

March 10, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Best And Worst Performing S&P 500 Stocks Since Trump's Election Win ↗

March 07, 2025

Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.

Via Benzinga

Topics Government Stocks

Gilead Sciences Unusual Options Activity ↗

February 24, 2025

Via Benzinga

How Is The Market Feeling About Gilead Sciences? ↗

February 19, 2025

Via Benzinga

16 Analysts Have This To Say About Gilead Sciences ↗

February 18, 2025

Via Benzinga

Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook. ↗

February 26, 2025

Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products.

Via Investor's Business Daily

Topics Artificial Intelligence

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

February 23, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

Via StockStory

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

February 22, 2025

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Via MarketBeat

Topics Death

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

February 18, 2025

Via Benzinga

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

February 18, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Bullish Setups ↗

February 16, 2025

You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now.

Via Talk Markets

Topics Stocks / Equities

Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday ↗

February 13, 2025

Via Benzinga

Moderna (MRNA) Q4 Earnings Report Preview: What To Look For

February 13, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.

Via StockStory

Top S&P500 movers in Wednesday's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗

February 12, 2025

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Via Benzinga

These S&P500 stocks have an unusual volume in today's session ↗

February 12, 2025

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Via Chartmill

Why Gilead Sciences (GILD) Stock Is Trading Up Today

February 12, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS,...

Via StockStory

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: vctr@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Gilead Sciences (NQ:GILD)

Headline News about Gilead Sciences

Sections

Services

Follow Us